benzofurans and arginyl-glycyl-aspartic-acid

To achieve the combination therapy of acute myocardial ischemia, arginyl-glycyl-aspartic acid (RGD) conjugated lipid was synthesized and RGD modified, salvianolic acid B (Sal B) and panax notoginsenoside (PNS) co-loaded lipid-polymer hybrid nanoparticles (RGD-S/P-LPNs) was fabricated an evaluated.. The LPNs are generally spherical in shape with uniform size distribution, have sizes of 100-200nm and zeta potentials range from -30.7∼ -39.8. In vitro release behaviors of drugs loaded LPNs are in a sustained release manner, which does not exhibit obviously cytotoxicity against H9c2 cardiomyocytes. RGD-S/P-LPNs group shows the most significant cardiac distribution and infarct therapy effect in vivo.. The results illustrated that RGD modified dual drugs co-loaded LPNs are stable, sustained release carriers. Cardiac distribution, pharmacokinetics, and infarct therapy effect results suggested that the RGD-S/P-LPNs could improve the in vivo therapeutic efficacy of the double drugs.

Topics: Animals; Benzofurans; Cell Line; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Therapy, Combination; Ginsenosides; Integrin alphaVbeta3; Lipids; Male; Myocardial Ischemia; Nanomedicine; Nanoparticles; Oligopeptides; Panax; Peptides; Phosphatidylethanolamines; Polyethylene Glycols; Polymers; Rats; Rats, Sprague-Dawley